MedTrace Logo

Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA

NCT05668910 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2022-12-30

No results posted yet for this study

Summary

To facilitate the early gastric cancer diagnosis, an assay based on assessing large-scale methylation and fragmentation profiles of the plasma cell free (cfDNA) will be developed and validated.

Conditions

Interventions

GENETIC

whole genomic methylation and fragmentation profile analysis of cfDNA

The assay for gastric cancer early detection will be built based on low-depth methylone sequencing followed with a multi-dimensional model construction with analysing several features such as methylation, fragmentation, and chromosomal copy number alternation.

Sponsors & Collaborators

  • The First Affiliated Hospital of Air Force Medicial University

    collaborator OTHER

  • GeneCast Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Gang Ji · The First Affiliated Hospital of Air Force Military Medical University (Xijing Hospital), Xi'an, China

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05668910 on ClinicalTrials.gov